Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
However, other demographic and clinical characteristics were comparable between study subjects treated with monthly and weekly oral BPs.Clinical characteristics of female patients with rheumatoid arthritis receiving oral bisphosphonatesMonthly BP(n = 158)Weekly BP(n = 238) p valueTotal subjects(n = 396)Age, years, mean ± SD66.5 ± 10.565.6 ± 11.90.41665.9 ± 11.3Disease duration, months, median (IQR)42 (12.5 to 82)35 (18 to 86)0.739 (18 to 84)Seropositive RA, n (%)131 (82.9)193 (81.1)0.646324 (81.8)DAS28-ESR, mean ± SD3.53 ± 1.673.84 ± 1.670.0893.72 ± 1.68Concurrent medications Methotrexate, n (%)93 (58.9)149 (62.6)0.454242 (61.1) Sulfasalazine, n (%)18 (11.4)37 (15.5)0.24255 (13.9) Hydroxychloroquine, n (%)86 (54.4)121 (50.8)0.484207 (52.3) Leflunomide, n (%)29 (18.4)49 (20.6)0.58479 (19.7) Glucocorticoid, n (%)138 (87.9)206 (86.6)0.697344 (86.9) Glucocorticoid dose, mg, median (IQR)7.5 (5 to 10)7.5 (5 to 10)0.6317.5 (5 to 10) Calcium/vitamin D, n (%)32 (20.3)42 (17.6)0.51474 (18.7)Previous history of fracture, n (%)11 (7)18 (7.6)0.82229 (7.3)Baseline DEXA, n (%)152 (96.2)203 (85.3)<0.001355 (89.6)BMD (T score) Spine, mean ± SD−1.8 ± 1.4−1.7 ± 1.40.629−1.7 ± 1.4 Femoral neck, mean ± SD−1.5 ± 1.1−1.4 ± 1.10.273−1.5 ± 1.1 Total hip, mean ± SD− 1.3 ± 1.1− 1.3 ± 1.10.595−1.3 ± 1.1Reimbursement for BPs108 (68.4%)146 (61.3%)0.154254 (64.1%)BMI, mean ± SD22.4 ± 2.822.2 ± 3.20.43522.3 ± 3Comorbidity Type 2 DM, n (%)19 (12)16 (6.7)0.06935 (8.8) HTN, n (%)42 (26.6)56 (23.5)0.34298 (24.7) RA rheumatoid arthritis, DEXA dual energy X-ray absorptiometry, BMD bone mineral density, BPs bisphosphonates, BMI body mass index, DM diabetes mellitus, HTN hypertension
Source: Results. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Study design awaiting verification.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.
Meta-analysis unclear · Blinding unclear / not reported · Human research reported
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
To ensure correct identification of BP initiation and sufficient data for estimation of adherence, all patients were required to have medical record for 12 months preceding and following their index date [].
Source: Methods.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Compliance and persistence with oral bisphosphonates for the treatment of osteoporosis in female patients with rheumatoid arthritis
Study design awaiting verification · BMC Musculoskeletal Disorders · 2017
Original publication title
Compliance and persistence with oral bisphosphonates for the treatment of osteoporosis in female patients with rheumatoid arthritis
© The Author(s). 2017
Original publication · Publisher record · CC BY 4.0 · CC0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What background does the paper provide?
Poor adherence with oral bisphosphonates (BPs) can mitigate their therapeutic benefit for osteoporosis and is a significant clinical burden. Most previous studies regarding adherence with oral BPs have focused on postmenopausal osteoporosis, but little attention has been given to patients with rheumatoid arthritis (RA). Thus, we investigated compliance and persistence with oral BPs in the treatment of osteoporosis and analyzed risk factors for poor adherence in female patients with (RA) in real setting.
Source: BackgroundAbstract: What methods does the paper describe?
This is a retrospective longitudinal study including 396 female patients with RA in whom oral BPs were newly initiated from Aug 2004 to Aug 2014 at a university rheumatology center in South Korea. Compliance was quantified using the 1-year medication possession ratio (MPR), while persistence was defined as duration from the initiation to the end of BPs therapy without interruption exceeding 56 days. Seropositve RA was defined as having a positive test result for the presence of either rheumatoid factor or anti-cyclic citrullinated peptide antibody.
Source: MethodsAbstract: Results
Of 396 RA patients, 221 (55.8%) were prescribed risedronate 35 mg weekly; 17 (4.3%) received alendronate 70 mg weekly; and 158 (39.9%) received ibandronate 150 mg monthly. The 1-year MPR was 70.1% and the proportion of RA patients with the 1-year MPR ≥ 0.8 was 60.1%. A total of 274 (69.2%) patients discontinued oral BPs during the study period and persistence with BPs was 63.3% at 1 year, 50.7% at 2 years and 33.3% at 3 years. The most common cause of non-persistence was adverse events (47.5%), followed by poor health literacy (40.5%) and cost (12%).
Both compliance and persistence with monthly oral BPs were significantly lower than those with weekly regimens (OR: 2.48, 95% CI: 1.59 to 3.89, P < 0.001 and HR: 2.19, 95% CI: 1.69 to 2.83, P < 0.001, respectively). Additionally, patients with seropositive RA showed better compliance and persistence with BPs compared with their seronegative counterparts.
Source: ResultsAbstract: Conclusions
Compliance and persistence with oral BPs in RA patients were suboptimal in real practice, thereby limiting the efficacy of osteoporosis treatment. Extending the dosing interval of BPs may improve medication adherence in RA patients.
Source: ConclusionsAuthors’ abstract
Background
Poor adherence with oral bisphosphonates (BPs) can mitigate their therapeutic benefit for osteoporosis and is a significant clinical burden. Most previous studies regarding adherence with oral BPs have focused on postmenopausal osteoporosis, but little attention has been given to patients with rheumatoid arthritis (RA). Thus, we investigated compliance and persistence with oral BPs in the treatment of osteoporosis and analyzed risk factors for poor adherence in female patients with (RA) in real setting.
Methods
This is a retrospective longitudinal study including 396 female patients with RA in whom oral BPs were newly initiated from Aug 2004 to Aug 2014 at a university rheumatology center in South Korea. Compliance was quantified using the 1-year medication possession ratio (MPR), while persistence was defined as duration from the initiation to the end of BPs therapy without interruption exceeding 56 days. Seropositve RA was defined as having a positive test result for the presence of either rheumatoid factor or anti-cyclic citrullinated peptide antibody.
Results
Of 396 RA patients, 221 (55.8%) were prescribed risedronate 35 mg weekly; 17 (4.3%) received alendronate 70 mg weekly; and 158 (39.9%) received ibandronate 150 mg monthly. The 1-year MPR was 70.1% and the proportion of RA patients with the 1-year MPR ≥ 0.8 was 60.1%. A total of 274 (69.2%) patients discontinued oral BPs during the study period and persistence with BPs was 63.3% at 1 year, 50.7% at 2 years and 33.3% at 3 years. The most common cause of non-persistence was adverse events (47.5%), followed by poor health literacy (40.5%) and cost (12%).
Both compliance and persistence with monthly oral BPs were significantly lower than those with weekly regimens (OR: 2.48, 95% CI: 1.59 to 3.89, P < 0.001 and HR: 2.19, 95% CI: 1.69 to 2.83, P < 0.001, respectively). Additionally, patients with seropositive RA showed better compliance and persistence with BPs compared with their seronegative counterparts.
Conclusions
Compliance and persistence with oral BPs in RA patients were suboptimal in real practice, thereby limiting the efficacy of osteoporosis treatment. Extending the dosing interval of BPs may improve medication adherence in RA patients.
Publication and source details
Original title: Compliance and persistence with oral bisphosphonates for the treatment of osteoporosis in female patients with rheumatoid arthritis
Ji-Heh Park; Eun-Kyoung Park; Dong-Wan Koo; Shinwon Lee; Sun-Hee Lee; Geun-Tae Kim; Seung-Geun Lee
BMC Musculoskeletal Disorders · 2017
© The Author(s). 2017https://creativecommons.org/licenses/by/4.0/ Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.This work was supported by clinical research grant from Pusan National University Hospital 2016Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-12T19:43:44.250683+00:00
DOI: 10.1186/s12891-017-1514-4 · PMC5387221